Penumbra Launches FORWARD Study to Evaluate Distal Stroke Treatment
Event summary
- Penumbra initiated the FORWARD study on July 7, 2026, to evaluate mechanical thrombectomy for distal acute ischemic stroke.
- The study will enroll up to 250 participants across approximately 40 sites globally.
- FORWARD focuses on Penumbra's RED reperfusion catheter portfolio, including the THUNDERBOLT CAVT platform.
- Distal occlusions account for 25-40% of acute ischemic strokes, with M2 occlusions occurring in 3-7% of cases annually.
The big picture
Penumbra's FORWARD study targets a critical gap in stroke treatment, where distal occlusions have historically lacked effective interventions. With mechanical thrombectomy established for large vessel occlusions, this study could expand the application of Penumbra's technology into a larger patient population. The global burden of stroke—11.9 million new cases annually—creates significant market potential if the study succeeds in demonstrating safety and efficacy.
What we're watching
- Technology Efficacy
- Whether Penumbra's CAVT technology can demonstrate superior outcomes in treating distal occlusions compared to existing methods.
- Market Expansion
- The pace at which positive FORWARD study results could drive wider adoption of mechanical thrombectomy for M2 occlusions.
- Regulatory Impact
- How the study outcomes might influence future FDA and international regulatory approvals for Penumbra's devices.